Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | The microbiota: a new player in GvHD pathophysiology

Florent Malard • 23 Aug 2020
EBMT 2020

Florent Malard, MD, PhD, of Saint-Antoine Hospital and Sorbonne University, Paris, France, explores the role of the microbiota in graft-versus-host disease (GvHD) pathophysiology. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Florent Malard

Outcomes of a real-world comparison of standard-of-care ide-cel and cilta-cel in R/R myeloma
0:55
Outcomes of a real-world comparison of standard-of-care ide-cel and cilta-cel in R/R myeloma
Florent Malard • 24 Mar 2026
MaaT013 pooled allogeneic microbiotherapy in refractory GI acute GvHD: results of the ARES trial
1:50
MaaT013 pooled allogeneic microbiotherapy in refractory GI acute GvHD: results of the ARES trial
Florent Malard • 24 Mar 2026
Results of a survey investigating fertility and outcomes after CAR T-cell therapy
1:13
Results of a survey investigating fertility and outcomes after CAR T-cell therapy
Florent Malard • 7 Dec 2025
Results of ARES: allogeneic microbiotherapy for ruxolitinib-refractory GvHD with GI involvement
2:08
Results of ARES: allogeneic microbiotherapy for ruxolitinib-refractory GvHD with GI involvement
Florent Malard • 7 Dec 2025

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals